0001209191-17-049665.txt : 20170818
0001209191-17-049665.hdr.sgml : 20170818
20170818190328
ACCESSION NUMBER: 0001209191-17-049665
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170816
FILED AS OF DATE: 20170818
DATE AS OF CHANGE: 20170818
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hora Maninder
CENTRAL INDEX KEY: 0001443159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 171041964
MAIL ADDRESS:
STREET 1: PDL BIOPHARMA, INC.
STREET 2: 1400 SEAPORT BOULEVARD
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-16
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001443159
Hora Maninder
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
0
1
0
0
SVP Pharma Dev & Mfg Ops
Common Stock
2017-08-16
4
S
0
2956
19.32
D
58233
D
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
This transaction was executed in multiple trades at prices ranging from $19.02 to $19.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
This number includes 6,000 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
Mark A. Wilson, Attorney-in-Fact
2017-06-18